Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
FXS及びASDと診断された患者におけるsAPP、sAPPアルファ及びBDNFレベルの調節
Document Type and Number:
Japanese Patent JP6548575
Kind Code:
B2
Abstract:
A method of treating and monitoring patient diagnosed with Autistic Spectrum disorder or Fragile X syndrome comprising measuring plasma biomarker levels of BDNF, sAPP, and sAPP alpha and adjusting the amount of a therapeutic compound according to the plasma levels of BDNF, sAPP and sAPPs. In one embodiment, the therapeutic compound is acamprosate.

Inventors:
Ericsson, Craig, A.
Lahiri, Debomoi, Kay.
Application Number:
JP2015524368A
Publication Date:
July 24, 2019
Filing Date:
July 22, 2013
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
International Classes:
A61K31/185; A61P25/18; G01N33/53
Other References:
Ray B, et al.,Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: proposal of a specific, anabolic pathway and putative biomarker,PLoS ONE,2011年 6月22日,Vol.6, No.6,e20405
Erickson CA, et al.,Brief report: acamprosate in fragile X syndrome,Journal of Autism and Developmental Disorders,2010年11月,Vol.40, No.11,p.1412-1416
Erickson CA, et al.,An open-label naturalistic pilot study of acamprosate in youth with autistic disorder,Journal of Child and Adolescent Psychopharmacology,2011年,Vol.21, No.6,p.565-569
Sokol DK, et al.,Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links,Neurology,2011年 4月12日,Vol.76, No.15,p.1344-1352
Attorney, Agent or Firm:
Hiroshi Kobayashi
Norio Omori
Koichi Iwata
Yasuhito Suzuki